Sara Samir Mohamed Elmenshawy, Mohamed Farouk Ahmed Abdelsalam, Tarek Refaat El Nagdy, Mohamed Abdel Salam Elgohary, Nagwa Ali Sabri, Amal El-Kholy
{"title":"Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19.","authors":"Sara Samir Mohamed Elmenshawy, Mohamed Farouk Ahmed Abdelsalam, Tarek Refaat El Nagdy, Mohamed Abdel Salam Elgohary, Nagwa Ali Sabri, Amal El-Kholy","doi":"10.1080/20565623.2024.2418798","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.<b>Materials & methods:</b> A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period.<b>Results:</b> The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia.<b>Discussion:</b> Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir.<b>Conclusion:</b> It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease.<b>Trial registration number:</b> NCT04973462.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2418798"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572151/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2024.2418798","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.Materials & methods: A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period.Results: The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia.Discussion: Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir.Conclusion: It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease.Trial registration number: NCT04973462.
期刊介绍：
Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
